Bioanalytical Systems Stock Forecast, Price & News

-1.27 (-6.20 %)
(As of 04/21/2021 12:00 AM ET)
Today's Range
Now: $19.22
50-Day Range
MA: $18.74
52-Week Range
Now: $19.22
Volume644,549 shs
Average Volume122,925 shs
Market Capitalization$213.94 million
P/E RatioN/A
Dividend YieldN/A
Bioanalytical Systems, Inc., doing business as Inotiv, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. BioVaxys has an agreement with Inotiv to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Bioanalytical Systems logo

Industry, Sector and Symbol

Industry Commercial physical research
Current SymbolNASDAQ:BASI
Year FoundedN/A



Sales & Book Value

Annual Sales$60.47 million
Cash Flow$0.03 per share
Book Value$0.69 per share


Net Income$-4,680,000.00


Market Cap$213.94 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable


Bioanalytical Systems, Inc. to Host Earnings Call
February 9, 2021 |
Inotiv Broadens Pathology Service Offerings
January 19, 2021 |
BASi Releases Earnings for Fourth Quarter of Fiscal 2020
December 21, 2020 |
See More Headlines


Overall MarketRank

1.22 out of 5 stars

Medical Sector

898th out of 2,024 stocks

Commercial Physical Research Industry

17th out of 42 stocks

Analyst Opinion: 1.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
-1.27 (-6.20 %)
(As of 04/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BASI News and Ratings via Email

Sign-up to receive the latest news and ratings for BASI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Bioanalytical Systems (NASDAQ:BASI) Frequently Asked Questions

Is Bioanalytical Systems a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bioanalytical Systems in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bioanalytical Systems stock.
View analyst ratings for Bioanalytical Systems
or view top-rated stocks.

What stocks does MarketBeat like better than Bioanalytical Systems?

Wall Street analysts have given Bioanalytical Systems a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bioanalytical Systems wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Bioanalytical Systems' next earnings date?

Bioanalytical Systems is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Bioanalytical Systems

How were Bioanalytical Systems' earnings last quarter?

Bioanalytical Systems, Inc. (NASDAQ:BASI) released its earnings results on Monday, February, 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.16. The firm earned $17.89 million during the quarter. Bioanalytical Systems had a negative trailing twelve-month return on equity of 42.74% and a negative net margin of 7.75%.
View Bioanalytical Systems' earnings history

How has Bioanalytical Systems' stock been impacted by COVID-19 (Coronavirus)?

Bioanalytical Systems' stock was trading at $4.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BASI shares have increased by 345.9% and is now trading at $19.22.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BASI?

1 equities research analysts have issued 1-year price targets for Bioanalytical Systems' stock. Their forecasts range from $17.00 to $17.00. On average, they anticipate Bioanalytical Systems' share price to reach $17.00 in the next year. This suggests that the stock has a possible downside of 11.6%.
View analysts' price targets for Bioanalytical Systems
or view top-rated stocks among Wall Street analysts.

Who are Bioanalytical Systems' key executives?

Bioanalytical Systems' management team includes the following people:
  • Mr. Robert W. Leasure Jr., Pres, CEO & Director (Age 61, Pay $529.23k)
  • Dr. John E. Sagartz D.V.M., DiplomateACVP, DVM, Ph.D., Chief Strategy Officer & Director (Age 56, Pay $289.82k)
  • Mr. Joseph Earl Flynn, Chief Commercial Officer (Age 56, Pay $310k)
  • Dr. Peter T. Kissinger, Founder, Chairman Emeritus & Scientific Advisor (Age 76)
  • Ms. Beth A. Taylor CPA, CFO, VP of Fin. & Sec. (Age 56)
  • Mr. John Gregory Beattie, Chief Operating Officer
  • Mr. William D. Pitchford, Chief HR Officer (Age 66)
  • Mr. Philip A. Downing, Sr. VP of Nonclinical Services (Age 51)
  • Dr. Michael A. Baim Ph.D., Sr. VP of Analytical Operations (Age 64)
  • Dr. J. Scott Daniels, Sr. VP of DMPK

What is Jacqueline Lemke's approval rating as Bioanalytical Systems' CEO?

6 employees have rated Bioanalytical Systems CEO Jacqueline Lemke on Jacqueline Lemke has an approval rating of 20% among Bioanalytical Systems' employees. This puts Jacqueline Lemke in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Bioanalytical Systems' key competitors?

What other stocks do shareholders of Bioanalytical Systems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bioanalytical Systems investors own include Riot Blockchain (RIOT), The Boeing (BA), NVIDIA (NVDA), (OSTK), Enphase Energy (ENPH), Pure Storage (PSTG), Mastercard (MA), Main Street Capital (MAIN), QUALCOMM (QCOM) and Toll Brothers (TOL).

What is Bioanalytical Systems' stock symbol?

Bioanalytical Systems trades on the NASDAQ under the ticker symbol "BASI."

How do I buy shares of Bioanalytical Systems?

Shares of BASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bioanalytical Systems' stock price today?

One share of BASI stock can currently be purchased for approximately $19.22.

How much money does Bioanalytical Systems make?

Bioanalytical Systems has a market capitalization of $213.94 million and generates $60.47 million in revenue each year. The company earns $-4,680,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does Bioanalytical Systems have?

Bioanalytical Systems employs 397 workers across the globe.

What is Bioanalytical Systems' official website?

The official website for Bioanalytical Systems is

Where are Bioanalytical Systems' headquarters?

Bioanalytical Systems is headquartered at 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906.

How can I contact Bioanalytical Systems?

Bioanalytical Systems' mailing address is 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906. The company can be reached via phone at 765-463-4527 or via email at [email protected]

This page was last updated on 4/22/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.